Interaction of the capsular polysaccharide of Haemophilus influenzae type B with C1q
- PMID: 8172562
Interaction of the capsular polysaccharide of Haemophilus influenzae type B with C1q
Abstract
The Gram-negative pleomorphic bacterium Haemophilus influenza type b (Hib) is the most common cause of bacterial meningitis in children below the age of 2. Virtually all infants between 3 and 18 month of age lack anticapsular antibodies. This is typical for the response to a T-cell-independent antigen. 3-5% of this group harbour Hib in the nasopharynx, but the incidence of disease is 1000-fold less. This implicates other factors in host susceptibility in addition to the absence of such antibodies. Under physiological conditions the purified complement subcomponent C1q interacts with polyribosylribitolphosphate (PRP), the capsular polysaccharide of Hib. The complex formation of C1q, the most basic serum protein, with this polyanion was demonstrated by several methods: agarose gel electrophoresis followed by immunoprecipitation in the gel and Coomassie staining; western blot analysis of C1q-PRP complexes; complex formation in electrophoretic separation of PRP; retardation of electrophoretic mobility of PRP was checked by blotting of this polysaccharide. These results were confirmed by time- and dose-dependent alteration of antigenetic properties detected by C1q-Sandwich-ELISA after coincubation with PRP. Preincubation of serum treated Hib with C1q significantly enhanced the O2-metabolism of polymorphonuclear leucocytes in chemiluminescence assay. Infants of the susceptible age group develop antibodies to several Hib outer membrane proteins (OMP) and lipooligosaccharides (LOS) in response to infection. The complement activation by immune complexes might be inhibited by the formation of C1q-PRP complexes. Our results do not support the thesis that C1q can be activated by the interaction with PRP as shown before for other polyanions. Differing C1q to PRP ratios could be a possible explanation for different host susceptibilities.
Similar articles
-
Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.J Am Geriatr Soc. 2004 Nov;52(11):1883-7. doi: 10.1111/j.1532-5415.2004.52511.x. J Am Geriatr Soc. 2004. PMID: 15507066 Clinical Trial.
-
Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.Clin Infect Dis. 2008 Jan 15;46(2):186-92. doi: 10.1086/524668. Clin Infect Dis. 2008. PMID: 18171249
-
Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.Vaccine. 2006 Mar 10;24(11):1776-85. doi: 10.1016/j.vaccine.2005.10.023. Epub 2005 Oct 27. Vaccine. 2006. PMID: 16303216 Clinical Trial.
-
Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.Bull World Health Organ. 2000;78(3):364-71. Bull World Health Organ. 2000. PMID: 10812736 Free PMC article.
-
Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.Pediatrics. 2006 Apr;117(4):e717-24. doi: 10.1542/peds.2005-0348. Epub 2006 Mar 20. Pediatrics. 2006. PMID: 16549502
Cited by
-
Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway.Protein Cell. 2011 Apr;2(4):320-32. doi: 10.1007/s13238-011-1029-y. Epub 2011 May 15. Protein Cell. 2011. PMID: 21574022 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials